<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlSource>
  <Section SecID="390" OrdBy="100" Name="General">
    <Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Guideline for the laboratory diagnosis of functional iron deficiency.&lt;/div&gt;" />
    </Field>
    <Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I, British Committee for Standards in Haematology. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol. 2013 Jun;161(5):639-48. [76 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23573815&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="420" OrdBy="300" Name="Recommendations">
    <Field FieldID="151" OrdBy="310" ID="421" Name="Major Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Definitions for the quality of the evidence (&lt;strong&gt;A-C&lt;/strong&gt;) and strength of recommendation (strong [grade&lt;strong&gt; 1&lt;/strong&gt;], weak [grade&lt;strong&gt; 2&lt;/strong&gt;]) are given at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Variables for the Assessment of Functional Iron Deficiency or Iron-Restricted Erythropoiesis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Red Cell Variables&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Mean cell volume (MCV) and mean cell haemoglobin (MCH) values are useful at diagnosis and in assessing trends over periods of weeks or months. They have no use in assessing acute changes in iron availability secondary to therapy with erythropoiesis-stimulating agents (ESAs). (&lt;strong&gt;1B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The percentage of hypochromic red cells (%HRC) is the best-established variable for the identification of functional iron deficiency (FID) and thus has the greatest level of evidence. Reticulocyte haemoglobin content (CHr) is the next most established option. Both tests have limitations in terms of sample stability or equipment availability. Other parameters may be as good but there is no evidence that they are any better, and generally there is less evidence for newer red cell and reticulocyte parameters. (&lt;strong&gt;1B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A CHr value &amp;lt;29 pg predicts FID in patients receiving ESA therapy. A reticulocyte haemoglobin equivalent (Ret-He) value &amp;lt;25 pg is suggestive of classical iron deficiency and also predicts FID in those receiving ESA therapy. (&lt;strong&gt;1B&lt;/strong&gt;) A Ret-He value &amp;lt;30&amp;middot;6 pg appears to have the best predictive value for likelihood of response to intravenous iron therapy in chronic kidney disease (CKD) patients on haemodialysis. (&lt;strong&gt;1B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The measurement of red cell zinc protoporphyrin concentration provides a sensitive index of FID and may be used as an alternative to indices of red blood cell (RBC) hypochromia or reticulocyte haemoglobin content, although it is less sensitive than these to acute changes in iron availability. If used in the assessment of FID in CKD patients it is essential that measurements be made on washed cells, with the use of appropriate reference limits. (&lt;strong&gt;1B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Assessment of Iron Stores&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cytological Assessment of Iron Stores&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Bone marrow examination for the sole purpose of assessing iron stores is rarely justifiable. It may be helpful if there are concerns that a high serum ferritin value (&amp;gt;1200 &amp;micro;g/l) is not a true reflection of the bone marrow iron storage pool. (&lt;strong&gt;1B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Serum Ferritin&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The serum ferritin assay is essential in the assessment and management of patients with all forms of iron-restricted erythropoiesis (IRE) including FID. Values &amp;lt;12 &amp;micro;g/l indicate absent iron stores. (&lt;strong&gt;1A&lt;/strong&gt;) Values as high as 1200 &amp;micro;g/l in CKD patients do not exclude the possibility of FID and some such patients may respond to intravenous iron therapy. No recommendation as to the highest serum ferritin concentration beyond which it is unsafe to give a trial of intravenous iron therapy can be given. A serum ferritin concentration &amp;lt;100 &amp;micro;g/l in nondialysed patients or &amp;lt;200 &amp;micro;g/l in chronic haemodialysis patients is associated with a high likelihood of iron deficiency and a potentially good response to intravenous iron therapy. (&lt;strong&gt;1A&lt;/strong&gt;) Values above the suggested cut-offs given above should therefore not be used to guide iron therapy. Serum ferritin values &amp;gt;1200 &amp;micro;g/l should be used to ascertain whether investigation of potential iron overload should be undertaken. (&lt;strong&gt;1B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The serum ferritin concentration is not useful in predicting ESA responsiveness in cancer-related anaemia (&lt;strong&gt;1A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Soluble Transferrin Receptor&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The soluble transferrin receptor (sTfR) assay is relatively expensive, not widely available, and is not currently subject to external quality assessment (EQA) in the UK. An International Standard may improve assay standardization. The treatment of renal anaemia with ESAs, which increase sTfR, is a complicating factor. The assay may have a role, either alone or in combination with the ferritin assay, if automated measures such as %HRC, CHr or Ret-He are unavailable. (&lt;strong&gt;1B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Serum Iron, Total Iron-Binding Capacity (TIBC) and %Saturation (%Sat)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;In isolation the percentage saturation of transferrin is not recommended as a predictor of responsiveness to intravenous iron therapy in patients with CKD. It may be used to monitor response to ESA and/or iron therapy in CKD. It may be used to monitor response to ESA and/or iron in CKD. When used with either the serum ferritin concentration or measurement such as %HRC and CHr it may be useful in the diagnosis of FID. (&lt;strong&gt;1A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Erythropoietin&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul ytpe=&quot;disc&quot;&gt;&#xD;&#xA;    &lt;li&gt;The measurement of serum erythropoietin concentration in the setting of anaemia has limited value in the diagnosis of FID. (&lt;strong&gt;1A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Hepcidin&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The utility of hepcidin measurement as a diagnostic tool is currently uncertain and for the time being this technique remains a research investigation. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in context, it is useful to consider the uncertainty of knowledge and whether further research could change what we know or our certainty.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(A) High&lt;/strong&gt;: Further research is very unlikely to change confidence in the estimate of effect. Current evidence derived from randomized clinical trials without important limitations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(B) Moderate&lt;/strong&gt;: Further research may well have an important impact on confidence in the estimate of effect and may change the estimate. Current evidence derived from randomized clinical trials with important limitations (e.g., inconsistent results, imprecision &amp;ndash; wide confidence intervals or methodological flaws &amp;ndash; e.g., lack of blinding, large losses to follow up, failure to adhere to intention to treat analysis), or very strong evidence from observational studies or case series (e.g., large or very large and consistent estimates of the magnitude of a treatment effect or demonstration of a dose-response gradient).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(C) Low&lt;/strong&gt;: Further research is likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Current evidence from observational studies, case series or just opinion.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strong (grade 1)&lt;/strong&gt;: Strong recommendations (grade 1) are made when there is confidence do or do not outweigh harm and burden. Grade 1 recommendations can be applied uniformly to most patients. Regard as 'recommend'.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Weak (grade 2)&lt;/strong&gt;: Where the magnitude of benefit or not is less certain a weaker grade 2 recommendation is made. Grade 2 recommendations require judicious application to individual patients. Regard as 'suggest'.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="138" OrdBy="330" ID="423" Name="Clinical Algorithm(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An algorithm for management of iron-restricted erythropoiesis in patients with chronic kidney disease (CKD) on erythropoiesis-stimulating agents (ESAs) is provided in the original guideline document.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="396" OrdBy="400" Name="Scope">
    <Field FieldID="140" OrdBy="405" ID="397" Name="Disease/Condition(s)" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Functional iron deficiency (FID) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anaemia of chronic disease (ACD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chronic kidney disease (CKD) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: FID is a state in which there is insufficient iron incorporation into erythroid precursors in the face of apparently adequate body iron stores. FID is a major component of the anaemia of chronic disease (ACD).&lt;/p&gt;" />
    </Field>
    <Field FieldID="103" OrdBy="410" ID="398" Name="Guideline Category" Type="picklist-many">
      <FieldValue Value="Diagnosis" />
      <FieldValue Value="Evaluation" />
      <FieldValue Value="Management" />
      <FieldValue Value="Treatment" />
    </Field>
    <Field FieldID="113" OrdBy="415" ID="399" Name="Clinical Specialty" Type="picklist-many">
      <FieldValue Value="Family Practice" />
      <FieldValue Value="Hematology" />
      <FieldValue Value="Internal Medicine" />
      <FieldValue Value="Nephrology" />
      <FieldValue Value="Oncology" />
    </Field>
    <Field FieldID="114" OrdBy="420" ID="400" Name="Intended Users" Type="picklist-many">
      <FieldValue Value="Advanced Practice Nurses" />
      <FieldValue Value="Clinical Laboratory Personnel" />
      <FieldValue Value="Nurses" />
      <FieldValue Value="Physician Assistants" />
      <FieldValue Value="Physicians" />
    </Field>
    <Field FieldID="129" OrdBy="425" ID="401" Name="Guideline Objective(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To provide healthcare professionals with clear guidance on the management of functional iron deficiency (FID), in particular with respect to patients with chronic kidney disease (CKD), but also to other disease states in which erythropoietin-stimulating agents (ESAs) have been used&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="132" OrdBy="430" ID="402" Name="Target Population" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adult patients with chronic kidney disease (CKD) or other disease states in which erythropoiesis-stimulating agents (ESAs) have been used&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The guidance may not be appropriate to patients with inflammatory diseases and in all cases individual patient circumstances may dictate an alternative approach. This guideline is only applicable to adults, not children.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="133" OrdBy="435" ID="403" Name="Interventions and Practices Considered" Type="text">
      <FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Mean cell volume (MCV) and mean cell haemoglobin (MCH) values &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Percentage of hypochromic red cells (% HRC) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reticulocyte haemoglobin content (CHr) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Red cell zinc protoporphyrin concentration &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Serum ferritin assay &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Soluble transferrin receptor (sTfR) assay &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Percentage saturation of transferrin &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Serum erythropoietin concentration &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" />
    </Field>
    <Field FieldID="134" OrdBy="440" ID="404" Name="Major Outcomes Considered" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity and specificity of tests for assessment of iron &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inadequate iron supply &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Iron overload &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Effects of, or need for, supplementation with iron or erythropoiesis-stimulating agents (ESAs) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="405" OrdBy="500" Name="Methodology">
    <Field FieldID="109" OrdBy="505" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many">
      <FieldValue Value="Searches of Electronic Databases" />
    </Field>
    <Field FieldID="135" OrdBy="510" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;MEDLINE was searched systematically for publications in English from 1966-2011 using key words: functional iron deficiency and each of the parameters discussed.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="136" OrdBy="515" ID="408" Name="Number of Source Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="115" OrdBy="520" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice">
      <FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" />
    </Field>
    <Field FieldID="149" OrdBy="525" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in context, it is useful to consider the uncertainty of knowledge and whether further research could change what we know or our certainty.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(A) High&lt;/strong&gt;: Further research is very unlikely to change confidence in the estimate of effect. Current evidence derived from randomised clinical trials without important limitations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(B) Moderate&lt;/strong&gt;: Further research may well have an important impact on confidence in the estimate of effect and may change the estimate. Current evidence derived from randomised clinical trials with important limitations (e.g., inconsistent results, imprecision &amp;ndash; wide confidence intervals or methodological flaws &amp;ndash; e.g., lack of blinding, large losses to follow up, failure to adhere to intention to treat analysis), or very strong evidence from observational studies or case series (e.g., large or very large and consistent estimates of the magnitude of a treatment effect or demonstration of a dose-response gradient).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(C) Low&lt;/strong&gt;: Further research is likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Current evidence from observational studies, case series or just opinion.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="116" OrdBy="530" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many">
      <FieldValue Value="Systematic Review" />
    </Field>
    <Field FieldID="150" OrdBy="535" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used to quote levels and grades of evidence (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="112" OrdBy="540" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice">
      <FieldValue Value="Expert Consensus" />
    </Field>
    <Field FieldID="145" OrdBy="545" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline group was selected to be representative of United Kingdom (UK)-based experts in the clinical and laboratory fields of iron metabolism, chronic kidney disease (CKD), quality control and method evaluation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The writing group produced the draft guideline, which was subsequently revised by consensus by members of the Task Force of the British Committee for Standards in Haematology (BCSH).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="146" OrdBy="550" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strong (grade 1)&lt;/strong&gt;: Strong recommendations (grade 1) are made when there is confidence that the benefits do or do not outweigh harm and burden. Grade 1 recommendations can be applied uniformly to most patients. Regard as 'recommend'.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Weak (grade 2)&lt;/strong&gt;: Where the magnitude of benefit or not is less certain a weaker grade 2 recommendation is made. Grade 2 recommendations require judicious application to individual patients. Regard as 'suggest'.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="148" OrdBy="565" ID="417" Name="Cost Analysis" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="104" OrdBy="570" ID="418" Name="Method of Guideline Validation" Type="picklist-choice">
      <FieldValue Value="External Peer Review" />
      <FieldValue Value="Internal Peer Review" />
    </Field>
    <Field FieldID="130" OrdBy="575" ID="419" Name="Description of Method of Guideline Validation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline was reviewed by a sounding board of United Kingdom (UK) haematologists and members of both the British Committee for Standards in Haematology (BCSH) and the British Society for Haematology. Comments were incorporated where appropriate.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations">
    <Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations">
    <Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate diagnosis and management of functional iron deficiency (FID) in patients with chronic kidney disease (CKD) or other disease states in which erythropoiesis-stimulating agents (ESAs) have been used&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="432" OrdBy="900" Name="Qualifying Statements">
    <Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;While the advice and information in these guidelines is believed to be true and accurate at the time of going to press, neither the authors, the British Society for Haematology nor the publishers accept any legal responsibility for the content of these guidelines. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The guidance may not be appropriate to patients with inflammatory diseases and in all cases individual patient circumstances may dictate an alternative approach. This guideline is only applicable to adults, not children. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline">
    <Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many">
      <FieldValue Value="Clinical Algorithm" />
    </Field>
  </Section>
  <Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many">
      <FieldValue Value="Getting Better" />
    </Field>
    <Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many">
      <FieldValue Value="Effectiveness" />
    </Field>
  </Section>
  <Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability">
    <Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I, British Committee for Standards in Haematology. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol. 2013 Jun;161(5):639-48. [76 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23573815&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text">
      <FieldValue Value="2013 Jun" />
    </Field>
    <Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p">
      <FieldValue Value="British Society for Haematology Guidelines - Professional Association" />
    </Field>
    <Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;British Committee for Standards in Haematology&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;British Committee for Standards in Haematology Writing Group&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Writing Group Members&lt;/em&gt;: D. Wayne Thomas, Derriford Hospital, Plymouth; Rod F. Hinchliffe, Sheffield Children's Hospital, Sheffield; Carol Briggs, University College Hospital, London; Iain C. Macdougall, King's College Hospital, London; Tim Littlewood, John Radcliffe Hospital, Oxford; Ivor Cavill, University Medical School, Cardiff, UK&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://onlinelibrary.wiley.com/doi/10.1111/bjh.12311/full&quot; title=&quot;British Committee for Standards in Haematology Web site&quot;&gt;British Committee for Standards in Haematology Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the British Committee for Standards in Haematology; Email: &lt;a href=&quot;mailto:bcsh@b-s-h.org.uk&quot;&gt;bcsh@b-s-h.org.uk&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on June 21, 2013.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is copyrighted by the British Committee for Standards in Haematology. For more information, contact the BCSH Secretary, 100 White Lion Street, London, UK, N1 9PF; Email: &lt;a href=&quot;mailto:bcsh@b-s-h.org.uk&quot;&gt;bcsh@b-s-h.org.uk&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NGC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>